CERo Therapeutics Holdings, Inc. (CERO)
NASDAQ: CERO · IEX Real-Time Price · USD
1.540
-0.160 (-9.41%)
Apr 18, 2024, 4:00 PM EDT - Market closed
Company Description
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer.
Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors.
The company is based in South San Francisco, California.
CERo Therapeutics Holdings, Inc.
| Country | United States |
| Founded | 2017 |
| Industry | Other |
| Employees | 8 |
| CEO | Brian G. Atwood |
Contact Details
Address: 201 Haskins Way, Suite 230 South San Francisco, California 94080 United States | |
| Phone | 650-407-2376 |
| Website | cero.bio |
Stock Details
| Ticker Symbol | CERO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001870404 |
| CUSIP Number | 206018103 |
| ISIN Number | US71902K1051 |
| Employer ID | 87-1088814 |
| SIC Code | 2836 |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 15, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 10, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Apr 3, 2024 | PRE 14A | Other preliminary proxy statements |
| Apr 2, 2024 | 8-K/A | [Amend] Current report |
| Apr 2, 2024 | 10-K | Annual Report |
| Apr 2, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Feb 28, 2024 | 8-K | Current Report |
| Feb 27, 2024 | 8-K/A | [Amend] Current report |
| Feb 23, 2024 | D | Notice of Exempt Offering of Securities |
| Feb 22, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |